On May 1, 2025, 180 Life Sciences Corp. announced that the United States Patent and Trademark Office (USPTO) issued an official Notice of Allowance for U.S. Patent Application No. 17/556,584.
This patent covers a novel method for preventing or reducing Post-Operative Cognitive Dysfunction (POCD). The allowance strengthens the company's existing, legacy biotechnology intellectual property assets.
This development supports the company's strategy to continue building shareholder value through scientific innovation and patent protection for its legacy IP. These assets are being positioned for potential future partnering, licensing, or strategic transactions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.